Section Arrow
CRDL.NASDAQ
- Cardiol Therapeutics
Quotes are at least 15-min delayed:2025/12/26 17:05 EST
After Hours
Last
 1.01
+0.0169 (+1.70%)
Bid
0.985
Ask
1.01
High 1.01 
Low 0.9931 
Volume 10.00K 
Regular Hours (Closed)
Last
 0.9931
-0.0169 (-1.67%)
Day High 
1.0187 
Prev. Close
1.01 
1-M High
1.12 
Volume 
346.21K 
Bid
0.985
Ask
1.01
Day Low
0.9801 
Open
1-M Low
0.88 
Market Cap 
101.00M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.03 
20-SMA 1.02 
50-SMA 1.05 
52-W High 1.59 
52-W Low 0.7709 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.41/-0.44
Enterprise Value
101.12M
Balance Sheet
Book Value Per Share
0.07
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CGCCanopy Growth Corp1.19-0.12-9.16%-- 
After Hours 1.1903 +0.0003 +0.03%
HIMSHims & Hers Health34.31-0.36-1.04%65.13PE
After Hours 34.11 -0.2 -0.58%
IXHLIncannex Healthcare0.3988-0.0118-2.87%-- 
After Hours 0.4 +0.0012 +0.30%
TLRYTilray Brands Inc.9.6-0.55-5.42%-- 
After Hours 9.53 -0.07 -0.73%
DVAXDynavax Technologies Corp15.38----48.45PE
After Hours 15.36 -0.02 -0.13%
Industry overview quotes are at least 15 minutes delayed
Business Description
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate,CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.